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Human plasmacytoid DCs (PDCs) represent a 
central cell type of the immune system (1, 2) 
that can participate to two of its critical activ-
ities. First, they can produce substantial amounts 
of type I IFN in response to a variety of patho-
gens, including viruses or parasites (3–6). PDC 
recognition of viruses is mediated primarily by 
recognition of the RNA or DNA genomes by 
Toll-like receptor (TLR)7 and TLR9, respec-
tively (1, 2). Second, after activation by viruses, 
cytokines, or CD40L, PDCs diff  erentiate into 
DCs and initiate adaptive immune responses 
leading to CD4 and CD8 T cell activation (1, 2, 7). 
The mechanisms governing these two func-
tions, activation of the innate response refl  ected 
by IFN-α production and of the adaptive 
  response by increased costimulatory molecule 
expression and antigen presentation, are not 
clearly defi  ned. This ability of PDCs to link the 
innate and adaptive immune response has many 
potential clinical applications. Clinical trials us-
ing synthetic TLR9 ligands, CpG-containing 
immunostimulatory oligonucleotide sequences 
(ISS), are currently being conducted in allergy, 
asthma, cancer, and infectious diseases.
Studies with ISS have revealed an impor-
tant feature of PDC responses through TLR9. 
Three diff  erent classes of ISS with diff  erent pri-
mary sequence motifs and diff  erent secondary 
and tertiary structures have been defi  ned. These 
diff  erent classes of ISS produce quite diff  erent 
responses in human PDCs. CpG-A ISS contain 
poly-G tails that enable the formation of aggre-
gated structures (8) and induce high levels of 
IFN-α, but have poor activity with respect to in-
ducing the diff  erentiation of PDCs into DCs (9). 
In contrast, CpG-B ISS induce strong PDC dif-
ferentiation, but are weak inducers of IFN-α (9). 
More recently, a third class of ISS, termed 
CpG-C, has been described that combines high 
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IFN-α induction and effi   cient maturation of PDCs (10–12). 
These fi   ndings raise intriguing questions concerning the 
mechanism and biological signifi  cance of these diff  erent re-
sponses of PDCs to TLR9 ligands.
In mice, CpG-A and CpG-B can trigger diff  erent signal-
ing pathways involving genes regulated by IRF-7 or NF-κB, 
respectively (13). This correlates with observations that 
CpG-A and CpG-B ISS localize to distinct intracellular 
compartments in mouse bone marrow–cultured DCs (14). 
In humans, CpG-B have been shown to localize in early en-
dosomes (15); however, these studies were performed with 
cultured, mature PDCs, which have a much reduced IFN-α 
production in response to TLR9 (5). The regulation of the 
IFN-α response can vary dramatically between cell types and 
culture conditions, stressing the need to study primary cells 
to characterize the biological responses of human PDCs to 
TLR9 activation.
The studies reported here were undertaken to better un-
derstand the basis for the diff  erential PDC responses to each 
of the diff  erent classes of ISS. We evaluated whether the dif-
ferent biological responses induced by the three classes of ISS 
resulted from their sequence composition, their secondary/
tertiary structures, or their compartmentalization inside the 
cells. We used several strategies to modify the physical prop-
erties of these oligodeoxynucleotides (ODNs) without alter-
ing their sequence composition and to correlate their activity 
on PDCs with ODN structure and localization in endosomal 
compartments. We also used pH-sensitive liposome prepara-
tions to prevent ISS–TLR9 interactions in the specifi  ed in-
tracellular compartment to determine whether localization 
or valency was the primary determinant of the response 
to TLR9 stimulation. We chose two markers, transferrin re-
ceptor (TfR) and lysosome-associated membrane protein 
(LAMP)-1, to identify endosomal vesicles in PDCs. TfR has 
been associated in other cell types with early endosomes and/
or recycling endosomes and LAMP-1 has been associated 
with late endosomes and or lysosomes (16, 17). The precise 
association of TfR and LAMP-1 with specifi  c vesicles has 
not been clearly defi  ned in primary naive human PDCs; 
however, it is reasonable to expect these markers to delineate 
earlier versus later components of the endosome–lysosome 
pathway. By these means, we were able to defi  ne the key 
factors that control the nature (IFN-α production or diff  er-
entiation into DC) of human PDCs in response to TLR9 and 
that provide new insight into the mechanism of action of ISS 
and a better understanding of the checkpoints regulating 
PDC activation.
RESULTS
Multimeric display of TLR9 ligands correlates with their 
ability to induce IFN-𝗂 production from human PDCs
Three classes of ISS (CpG-A, -B, -C) with very diff  erent bi-
ological activities on enriched human PDCs have been de-
scribed. CpG-A and CpG-C ISS can induce high levels of 
IFN-α, whereas CpG-B are unable to do so. However, when 
CpG-B are mixed with PMXB, the ODN is complexed into 
large microparticles (Fig. 1 B), which transforms it into a po-
tent inducer of IFN-α. The levels of IFN-α induced by 
CpG-B/PMXB were similar to those induced by CpG-A 
and CpG-C (Fig. 1 A), whereas PMXB provided relatively 
little enhancement to IFN-α induction by CpG-A and CpG-C 
(Fig. 1 A). To determine whether this eff  ect was specifi  c to 
PMXB formulations, we covalently conjugated CpG-B to 
the polysaccharide Ficoll to create a large molecule with mul-
tiple side chains. CpG-B–Ficoll signifi  cantly enhanced IFN-α 
production by PDCs, although less potently than PMXB for-
mulation (Fig. 1 C). Conversely, when CpG-A was   rendered 
single stranded by heating and flash cooling, a dramatic 
  reduction of IFN-α production was observed (Fig. 1 D). As a 
confi  rmation, a stable single- stranded form of CpG-A was 
Figure 1.  Structural complexity of TLR9 ligands correlates with 
their ability to induce IFN-𝗂 production from PDCs. 5 × 104 purifi  ed 
PDCs were cultured with different concentrations of ISS either alone or in 
combination with PMXB (100 μg/ml) (A, D, E). (B) Representation of mi-
croparticles composed of CpG-B and PMXB using electronic microscopy 
(Hitachi S-5000). Cells were also stimulated with the indicated concentra-
tions of (C) CpG-B either alone or conjugated with fi  coll, (D and E) with 
the single stranded form of CpG-A (CpG-A ss) and (E) using CpG-A where 
the last six bases were replaced by 7-deaza-guanosines (CpG-A [7dG]). 
After 16 h, supernatants were harvested and IFN-α production was evalu-
ated using immunoassay. Averages of 14 (A) and 5 (C–E) independent 
donors are shown. *, P < 0.05.JEM VOL. 203, August 7, 2006  2001
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produced by replacing the poly-G sequence at the 3′
end of the D19 sequence with 7-deazaguanosine residues 
(CpG-A/7dG). As observed with CpG-A ss, CpG-A/7dG 
did not induce IFN-α (Fig.1 E). Incorporation of either 
CpG-A ss or CpG-A/7dG into PMXB microparticles re-
stored them to a multimeric form and restored their ability to 
induce IFN-α (Fig. 1, D and E). This increase of IFN-α did 
not result from increased cellular uptake of the ISS (reference 
18 and unpublished data). The loss of stimulatory activity of 
native CpG-A is limited to IFN-α as similar levels of IL-6 
are produced after stimulation with CpG-A or CpG-A ss 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20060401/DC1). These data suggest that the ability of 
ISS to induce IFN-α is not intrinsic to the sequence compo-
sition, but depends upon the ability of ISS to form multi-
meric structures.
ISS forming highly aggregated structures have decreased 
capability to induce maturation of human PDCs 
and subsequent T cell activation
We and others have previously shown that the three classes of 
ISS have opposite eff  ects on the induction of IFN-α and 
maturation, with CpG-B being the most potent in inducing 
PDC maturation. In contrast with their eff  ects on IFN-α 
production, we observed that CpG-B/PMXB formulations 
had a reduced activity for PDC maturation as compared with 
CpG-B alone, both by percentage of cells expressing CD80 
and CD86 and by mean fl  uorescence intensity (Fig. 2, A 
and B). Conversely, CpG-A are known to be poor inducers 
of maturation (Fig. 2 C); however, the single-stranded form 
of CpG-A as well as CpG-A/7dG ODNs induced PDC mat-
uration (Fig. 2, C and D) comparable to that of CpG-B. As 
with CpG-B (Fig. 2, A and B), the formulation of these two 
single-stranded ODN with PMXB led to a reduction of mat-
uration activity as compared with free ODN (Fig. 2, C and 
D). We have shown previously that the level of maturation 
of PDCs after ISS stimulation can aff  ect their ability to acti-
vate naive CD4+ T cells with CpG-B and CpG-C being 
stronger than CpG-A to promote T cell proliferation (10). 
Interestingly, when PDC were stimulated with single-
stranded CpG-A, they activated T cells as well as PDCs stim-
ulated with either CpG-B and CpG-C (Fig. 3, A and B). 
Conversely, the incorporation of CpG-B into PMXB micro-
particles led to a loss of T cell proliferation (Fig. 3, A and B). 
Altogether, these data strongly suggest that the nature of 
the biological response of PDCs to ISS largely depends on 
Figure 2.  ISS forming highly aggregated structures have decreased 
capability to induce maturation of human PDCs. Purifi  ed PDCs 
(105 cells) were stimulated with ISS (0.1–2 μM) alone or combined with 
PMXB. After 16 h, cells were characterized for CD80 and CD86 expression 
by fl  ow cytometry analysis. A and C show representative dot plots, 
whereas B and D show cumulative mean fl  uorescence intensities. One 
representative (A and C) and averages of four independent donors 
(B and D) are shown. *, P < 0.05.2002  HUMAN PDC RESPONSE TO TLR9 ACTIVATION | Guiducci et al.
the physical form of the TLR9 ligands, with aggregated 
structures being able to induce the most potent IFN-α re-
sponse and single-stranded structures favoring maturation 
into potent antigen-presenting cells.
The physical form of ISS correlates with their intracellular 
localization in human PDCs
A recent report demonstrated that the intracellular localiza-
tion of CpG-A and CpG-B in mouse conventional DCs 
(cDCs) and PDCs strictly correlated with their ability to in-
duce IFN-α (14). To investigate whether a diff  erential com-
partmentalization of ISS in human PDCs could account for 
the aforementioned distinctive biological responses, naive 
human PDCs were incubated with fl  uorescent ISS and stained 
for TfR or LAMP-1 to identify distinct endosomes. Using 
confocal microscopy, we show that CpG-A were primarily 
localized in the TfR-positive endosomes, but not the LAMP-
1–positive endosomal compartment (Fig. 4, A–D). This was 
evident even after incubating the cells with fl  uorescent CpG-
A for up to 4 h (unpublished data). CpG- B had a completely 
diff  erent distribution. It was found mainly in the late endo-
some compartment, as shown by a strong colocalization with 
Figure 4.  CpG-A and CpG-B are distributed in different compart-
ments in PDCs. Purifi  ed PDCs were cultured with fl  uorescent CpG-A 
(A and C) or CpG-B (E and G). Cells were fi  xed, stained intracellularly with 
(A and E) antitransferrin receptor (TfR) or (C and G) anti–LAMP-1 anti-
bodies, and imaged by confocal microscopy. Images were acquired using 
a ZEISS LSM 510 META confocal microscope. We used CpG-A-Rhodamine 
green-X and CpG-B-Alexa488. Intensity profi  les of the merged channel 
along three randomly chosen lines (1, 2, and 3 shown on each merged 
staining) were analyzed using the profi  le tools of the Zeiss LSM software. 
Examples are shown for (B) CpG-A and TfR, (D) CpG-A and LAMP-1, 
(F) CpG-B and TfR, and (H) CpG-B and LAMP1. The green line represents 
the intensity of the ISS, whereas the red line represents the intensity of 
the endosomal marker. Overlap of the two profi  les indicates spatial cor-
relation for the occurrence of the two fl  uorescent signals. Representative 
data of 5–10 individual donors are shown. 
Figure 3.  Differential induction of maturation by the different 
forms of CpG correlates with their ability to promote T cell activation. 
Purifi  ed PDCs (8 × 104 cells) were stimulated with ISS alone or combined 
with PMXB for 24 h. Naive CFSE-labeled allogenic CD4+ T cells were 
added (1:2) and incubated for an additional 4 d. Cells were gated on CD3 
and examined for the frequency of dividing cells based on CFSE dilution 
by fl  ow cytometry. (A) One representative and (B) averages of 16 indepen-
dent MLR reactions are shown. **, P < 0.01; ***, P < 0.001.JEM VOL. 203, August 7, 2006  2003
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LAMP-1 (Fig. 4, E–H). Interestingly, CpG-C, which has the 
activities characteristic of both CpG-A (IFN-α induction) 
and CpG-B (PDC maturation), was found in both the TfR 
(Fig. S2 A, available at http://www.jem.org/cgi/content/
full/jem.20060401/DC1) and LAMP-1 compartments (Fig. 
S2 C). Human primary PDCs have a small cytoplasm and 
some degree of colocalization could be the result of overlap-
ping staining patterns. To quantitate the distinction in stain-
ing patterns, we analyzed 25–75 cells acquired at high 
re  solution (as in Fig. 4) and showed that CpG-A is colocal-
ized with TfR in 73% of the cells; with LAMP-1, CpG-A is 
colocalized in only 18% of the cells. Conversely, CpG-B 
show an opposite pattern (<25% with TfR and 66% with 
LAMP-1) (Fig. 5). CpG-C was found in both compartments 
(Fig. S2 E). In addition, using the profi  le tools of the Zeiss 
LSM software, we show that the intensity profi   les of the 
merged channels (Fig. 4, A, C, E, and G) along randomly 
chosen lines reveal a clear spatial correlation for the occur-
rence of CpG-A and TfR (Fig. 4 B) and for CpG-B and 
LAMP1 (Fig. 4 H), whereas no correlation was observed be-
tween CpG-A and LAMP1 (Fig. 4 D) and CpG-B and TfR 
(Fig. 4 F). Spatial correlation with both TfR and LAMP-1 
was observed when using CpG-C (Fig. S2, B and D). These 
data demonstrate that the ISS localize in specifi  c organelles in 
primary human PDCs.
As previously discussed (Figs. 1 and 2), changes in the 
physical form of CpG-A and CpG-B dramatically altered the 
biological response of PDCs to these TLR9 ligands. To de-
termine whether these changes correlated with changes in 
subcellular localization, patterns of fl  uorescent CpG-A ss and 
PMXB-complexed CpG-B staining were studied. The sin-
gle-stranded form of CpG-A, which no longer induced 
IFN-α but promoted maturation, was observed in the LAMP-
1–positive endosomes but not in the TfR-positive endosome 
compartments (Fig. 6 A). Less than 10% of the cells showed 
colocalization with TfR, whereas this was observed with 
LAMP-1 in >80% of the cells (Fig. 6 B). Conversely, CpG-B 
embedded in PMXB microparticles primarily remained in 
the early endosomes (Fig. 6 A) with colocalization with TfR 
in >90% of the cells (Fig. 6 B) and was not found in the 
LAMP-1–positive endosomes even after 4 h of incubation 
(Fig. 6 A and not depicted). These data suggest that the same 
primary sequence can be directed to diff  erent intracellular 
compartments depending on whether it is monomeric or 
multimeric. Thus, the distinctive functions of each CpG class 
are not intrinsic to its sequence, but depend on sequence-re-
lated second and tertiary structural features. In addition, these 
data suggest that the nature of the PDC response to TLR9 
activation is regulated by the location in which TLR9 and its 
ligand interact, with induction of IFN-α requiring interac-
tion of the ISS with TLR-9 in TfR-positive endosomes and 
Figure 5.  Differential intracellular localization of ISS in human PDCs. 
Purifi  ed PDCs were cultured with fl  uorescent ISS for 90 min, then fi  xed 
and stained intracellularly with antitransferrin receptor (TfR) or anti–
LAMP-1 antibodies and imaged by confocal microscopy as described in 
Fig. 4. Between 25 and 75 cells from at least fi  ve different donors were 
analyzed for colocalization between the ODN and either transferrin recep-
tor (TfR) or LAMP-1 (LP1).
Figure 6.  The secondary structure of ISS is regulating their intra-
cellular localization in human PDCs. (A and B) Purifi  ed PDCs were cultured 
with fl  uorescent ISS for 90 min. Cells were fi  xed, stained intracellularly 
with antitransferrin receptor (TfR) or anti-LAMP1 antibodies, and imaged 
by confocal microscopy. We used CpG-A ss-Rhodamine green-X from the 
same preparation as CpG-A used in Fig. 4 and CpG-B-Alexa488 premixed 
with PMXB for 30 min. Images were acquired using a ZEISS LSM 510 
META confocal microscope. (B) Between 100 and 200 cells were analyzed 
from three donors for colocalization between the ODN and either trans-
ferrin receptor (TfR) or LAMP-1 (LP1).2004  HUMAN PDC RESPONSE TO TLR9 ACTIVATION | Guiducci et al.
PDC maturation requiring ISS interaction with TLR9 in 
LAMP-1–positive endosomes.
ISS lose their ability to induce IFN-𝗂 from human PDCs 
when encapsulated into pH 5.75 liposomes while they 
increase their capacity to promote PDC maturation
In experiments shown in Figs. 4–6, there is a consistent cor-
relation between endosomal localization of the ISS and the 
nature of the PDC response to that ISS. However, the local-
ization of the ISS sequence was varied by changing its physi-
cal form, CpG-A, to a single-stranded form and CpG-B by 
formation of microparticles. It remains possible that mono-
meric and multimeric ISS deliver diff  erent signals through 
TLR9 regardless of subcellular localization. To test this pos-
sibility, we used a CpG-C ISS encapsulated into pH-sensitive 
liposomes (19) to prevent ISS–TLR9 interaction in vesicles 
with a luminal pH higher than a specifi  ed value. We selected 
a CpG-C as it can promote both IFN-α and maturation (10) 
and is naturally found in both early and late endosomes (Fig. 
S2). Using pH-sensitive liposomes allowed us to control the 
location of ISS interaction with TLR9, without aff  ecting 
physical form or valency of the ISS. There is a general agree-
ment that, in many eukaryotic cells, the pH in the early en-
dosomes range between 6.2 and 6.5, in late endosomes 
between 6.0 and 5.0, and in the lysosomes at a pH <5.0 (20), 
although no data are available specifi  cally on human PDCs. 
Based on pH of endosomes and lysosomes in other cell types, 
we prepared liposomes releasing their content either at a 
pH <5.0 (Fig. 7 B), so that the CpG-C would be released at 
a pH found only in lysosomes, or at a pH <6.0 (Fig. 7 C) to 
prevent interaction between the CpG-C and TLR9 in the 
early but not in the late endosomes. The pH range over 
which these liposomes are destabilized is quite narrow as a 
diff  erence in the 0.25–0.5 pH value is suffi   cient to permit the 
complete release of the ODN (Fig. 7, B and C).
We fi  rst tested these liposome preparations on B cells to 
determine whether the encapsulation of CpG-C ISS in lipo-
somes would prevent ISS–TLR9 interaction and therefore 
activation of the cells. CpG-C ISS encapsulated in lipo-
somes releasing at pH 4.5 had no detectable activity either 
for cytokine production or induction of maturation, show-
ing clearly that liposomes that remain stable in both early and 
late endosomes, preventing CpG-C interaction with TLR-9 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20060401/DC1). Mixing liposomes with free CpG-C did 
not impair IL-6 production or B cell maturation, demonstrat-
ing that liposomes do not interfere with signaling by ISS that 
is external to them (Fig. S3). However, CpG-C ISS encap-
sulated in liposomes releasing at pH 5.75 induced maturation 
and IL-6 production to a similar extent as CpG-C ISS alone 
(Fig. S3), showing that release of ISS in the late endosomes 
permitted complete B cell responses to occur. In addition, we 
have performed experiments using pH 4.5 liposomes contain-
ing both CpG-C ISS and the pore-forming protein listerioly-
sin (LLO). This will release the ISS in the cytoplasm through 
pores in the endosomal membrane without prior interaction 
with TLR9 in endosomes (21, 22). Interestingly, this prepara-
tion was also totally inactive (unpublished data), suggesting 
that the CpG-C needs to enter through the endocytic path-
way to have activity. A better defi  nition of the traffi   cking of 
these diff  erent liposome preparations will be needed in future 
studies to get a more detailed understanding of their behavior 
and of their properties once they get inside the cells.
 CpG-C ISS can induce both maturation and IFN-α pro-
duction from PDCs. Strikingly, CpG-C, when encapsulated 
in pH 5.75 liposomes, could not induce IFN-α from PDCs, as 
measured either by ELISA or by quantitative PCR (Fig. 8 A 
and not depicted), although it was even more active at 
Figure 7.  Encapsulation of CpG-C ISS in two pH-sensitive liposome 
preparations. The liposomes were prepared from mixtures of CHEMS, 
DOTAP, and PE as described in Materials and methods and purifi  ed 
through gel fi  ltration on a 9-ml Superose 6 column equilibrated with the 
0.125 M NaCl, 0.01 M Hepes, pH 8.4 buffer. (A–C) Representation of ab-
sorbance monitored at 310 nm (thick line) and 260 nm (thin line) over 
time is shown. ODN are detected at 260 nm only while the liposomes can 
be detected at both 260 and 310 nm. (A) Representation of one liposome 
preparation mixed with free ODN. (B) Representation of one liposome 
preparation stable until pH < 5.0. (C) Representation of another liposome 
preparation stable until pH < 6.0.JEM VOL. 203, August 7, 2006  2005
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  inducing PDC maturation (Fig. 8, B and C). This demon-
strates that CpG-C ISS must interact with TLR9 in vesicles 
with a pH >6.0 to induce IFN-α, but not maturation. This 
was specifi  c, as liposomes alone or CpG-C/Lipo 4.5 were to-
tally inactive (Fig. 8). This suggests that the ODN sequence of 
the diff  erent classes of ISS determine their activity indirectly 
by promoting specifi  c secondary or multimeric structures that 
control the intracellular localization of the ISS to the appropri-
ate endosomes. However, a single molecular form of CpG-C 
will stimulate IFN-α only if it encounters TLR-9 in less acidic 
endosomes, strongly indicating that it is the location of TLR-9 
signaling, not valency of the ligand that is directly responsible 
for the nature of biological response in PDCs.
D  I  S  C  U  S  S  I  O  N 
In the present study, we have investigated an important 
mechanism underlying the diversity of function of human 
PDCs by analyzing the basis for the diff  erent biological re-
sponses induced by three distinct classes of synthetic TLR9 
ligands. We show that the nature of PDC response to TLR9 
activation depends primarily on the intracellular compart-
ment in which the ISS–TLR9 interaction occurs. Whether 
an ISS is localized to early endosomes, late endosomes, or 
both is a function of the physical form of the molecule, but is 
not directly a function of the sequence motifs or backbone 
chemistry of the molecule. Sequence and backbone are im-
portant, however, as both factors infl  uence the equilibrium 
between simple and higher order structures. Strikingly, the 
two critical functions of PDCs, IFN-α production and anti-
gen presentation, appear to be regulated by diff  erent signaling 
pathways associated with the diff  erent endosomal compart-
ments. Such control is extremely tight as it is possible to 
  uncouple the two responses by properly manipulating the in-
tracellular distribution of the ISS. Thus, when a CpG-B with 
poor IFN-α induction is embedded in microparticles using 
PMXB, it becomes an inducer of high levels of IFN-α from 
PDCs while decreasing the maturation of these cells and their 
subsequent T cell priming capability, as compared with free 
CpG-B. Alternately, CpG-A, made single stranded either by 
sequence modifi  cation or heating, lose their ability to stimu-
late IFN-α production but gain strong maturation induction 
and T cell priming activity. Interestingly, single-stranded 
CpG-A embedded in PMXB regains its ability to induce 
high levels of IFN-α with low levels of PDC maturation. In 
addition, we show that there is a consistent correlation be-
tween the nature of the PDC response to ISS and the intra-
cellular localization where the interaction between ISS and 
TLR9 primarily occurs. Multimeric structures such as CpG-A 
or CpG-B/PMXB microparticles are preferentially retained 
in TfR-positive endosomes of PDCs and this correlates with 
induction of high IFN-α levels and ineffi   cient stimulation 
of costimulatory molecule expression. Conversely, single-
stranded ODN such as CpG-B or CpG-A ss and CpG-A 
(7-dG) are strong inducers of maturation but cannot activate 
PDCs to produce IFN-α and these ODNs are consistently 
found preferentially in the LAMP-1–positive compartments. 
Figure 8.  CpG-C ISS lose their ability to induce IFN-𝗂 from human 
PDCs while retaining the ability to induce maturation when encap-
sulated into pH 5.75 liposomes. Purifi  ed PDCs (5 × 104 cells) were 
cultured with CpG-C (0.5 μg/ml) alone, empty liposomes, CpG-C mixed 
with empty liposomes, and with CpG-C encapsulated into two different 
liposome preparations (pH 4.5 or pH 5.75 sensitive) as described in Fig 7. 
(A) After 16 h, supernatants were harvested, IFN-α production was evalu-
ated using immunoassay, and (B and C) cells were characterized for CD80 
and CD86 expression by fl  ow cytometry. (B) Representative dot plots. 
(C) Averages of the cumulative mean fl  uorescence intensity for four inde-
pendent donors representative of 10 donors are shown. *, P < 0.05.2006  HUMAN PDC RESPONSE TO TLR9 ACTIVATION | Guiducci et al.
The presence of CpG-C in both types of   endosomes corre-
lates with their ability to trigger both IFN-α production and 
PDC maturation. In addition, the fact that CpG-C stimulate 
both types of PDC response provides evidence that the two 
signaling pathways are not mutually exclusive. Because of the 
long palindrome in the sequence, CpG-C can form either 
hairpin loop structures or can anneal to form dimers, but they 
do not form larger aggregates, thus they can be considered 
structurally intermediate between single-stranded CpG-B 
and multimeric CpG-A (11).
CpG-A form large nanoparticle structures with an aver-
age diameter of 50 nm and PMXB forms microparticles rang-
ing from 100 to 500 nm (8, 18). CpG-B conjugated with 
fi  coll has a molecular weight of 500–1,000 kD and an overall 
size of 20 nm (unpublished data). It is thus possible that TLR9 
interaction with multimeric ISS structure would signal only 
through the IRF7 but not the IRF5–NFκB pathway regard-
less of the intracellular compartment where the interaction 
occurs. Alternatively, the intracellular compartment where 
the diff  erent signaling complexes are engaged could be the 
key factor in triggering a diff  erent signaling pathway. Honda 
et al. have recently shown that to induce IFN-α, mouse cells 
need to activate the transcription factor IRF-7. Indeed, they 
show that in RAW 264.7 cells transfected with fl  uorescent-
tagged MyD88 and IRF-7, the two proteins colocalize in 
early endosome vesicles, suggesting the possibility that the 
TLR9–MyD88–IRF-7–dependent IFN pathway is started 
exclusively in the early endosome (14). In mice, although 
both cDCs and PDCs express TLR9, only the latter are able 
to produce IFN-α in response to TLR9 ligands with CpG-A 
being found in the late endosomes in the cDCs. When CpG-A 
are complexed with DOTAP, they are retained in the early 
endosome and stimulate cDCs to produce comparable levels 
of IFN-α to PDCs (14). Thus, the rules governing physical 
form and endosomal localization appear to be diff  erent be-
tween cell types and it is important to perform studies in the 
cell type of interest.
ISS has been suggested to enter the cells via clathrin-me-
diated endocytosis (15). Contrasting results reported TLR9 
to be either localized in the ER in resting cells and then re-
cruited to the site where CpG accumulate (15), or localized 
in an early endosome (23) together with the Myd88–IRF7 
complex (14). Although no data are available on human pri-
mary PDCs, it is generally accepted that endocytosed mole-
cules are fi  rst delivered to the early endosomes where the 
sorting process begins. The diff   erent endosomal compart-
ments display increasing acidity as they progress in the endo-
cytosis pathways (pH 6.3–6.5 for recycling compartments 
and pH 5.0–6.0 in late endosomes) and late endosomes can 
either recycle to the cell surface or proceed to the lysosomal 
compartment (pH < 5.0) where their content is degraded 
(20). This acidifi  cation can vary between cell subsets and 
level of activation/maturation of the cells (24).
CpG-C have the unique ability to localize in both early 
and late endosomes. By encapsulating CpG-C in pH 5.75–
sensitive liposomes, we were able to prevent the binding of 
ISS with TLR9 in the early/recycling endosomes without 
aff  ecting the physical form of the ODN. In this situation, the 
CpG-C failed to induce IFN-α from PDCs, but was more 
potent as an inducer of PDC maturation than CpG-C alone. 
Interestingly, oligonucleotides released from liposomes only 
at a more acidic pH (lipo 4.5 preparations) could no longer 
activate either maturation or IFN-α production in PDCs, 
suggesting that no signifi  cant TLR9 signaling occurs in lyso-
somal vesicles, in accordance with previous data showing that 
CpG binding to TLR9 is optimal between pH 6.5 and 5.5 (25). 
We attempted unsuccessfully to produce liposomes that 
would be able to release CpG-C at a pH >6.2 to evaluate 
  release in the TfR-positive endosomal compartment. The 
change of composition required to make such liposomes does 
not allow ODN encapsulation, as their ζ potential is too close 
to the neutral point.
Previous studies have shown that pH-sensitive liposomes 
release their contents in vesicles in a pH-dependent fashion 
(21, 26, 27). It is possible that the actual pH at which each of 
these liposomes lyses and releases its contents may be altered 
inside endosomal compartments; however, there is no basis 
to expect changes in the rank order of lysis of the diff  erent 
liposome preparations. It has been shown that DC matura-
tion is accompanied by a shift in lysosomal pH that becomes 
more acidic (thereby facilitating protein proteolysis) (24), 
  although the eff  ect of ISS stimulation on this process is cur-
rently unknown. As no interaction between ISS and TLR9 
is possible before the liposomes actually lyse and release their 
contents, this is unlikely to aff  ect the release of the initial 
load of CpG-C.
One question raised by our data is the following: Why 
are ISS confi  ned to early endosomes only when they are in 
multimeric form? The mechanisms governing the retention 
time in the diff  erent compartments are still poorly under-
stood. One possibility could be that only small structures are 
incorporated into multivescicular body inclusions and pro-
ceed through the endocytic pathway toward lysosomal com-
partments, whereas larger structures would not do this and 
would remain trapped into the early/recycling endosomes 
(16, 28). Another possibility could be the presence inside the 
early endosomes of a coreceptor for ISS that would have 
a higher avidity for large structures and would thereby pre-
vent their transit in the late endosomes. We cannot exclude, 
however, the possibility that PDCs possess even more spe-
cifi  c mechanisms that aff  ect the intracellular traffi   cking of 
CpG as suggested by recent studies showing that mouse my-
eloid DCs, although expressing TLR9, are unable to prop-
erly localize CpG-A despite its large structure in the early 
endosome (14).
Many viruses have evolved to be activated at pH that cor-
respond to early or late endosomes and use various mecha-
nisms to be retained in these endosomes to avoid the destructive 
eff  ect of lysosome acidifi  cation (29, 30). One of the best-
  described examples is the Semliki forest virus (30–32), entry of 
which can be prevented by inactivation of Rab5, an essential 
protein for the function of early endosomes (31, 32). Other JEM VOL. 203, August 7, 2006  2007
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viruses such as infl  uenza will go further down the pathway and 
reach late endosomes (31). PDCs are unique in their response 
to viruses, even though other cells, such as cDCs in mice, ex-
press TLR7, TLR9, and IRF7 and have the potential to pro-
duce similar levels of IFN-α (14). Still, the strikingly diff  erent 
type I IFN response after virus activation of cDCs and PDCs 
(33, 34) strongly suggests that PDCs are optimized to respond 
to virus infections. In light of our data and published observa-
tions, one model would be that PDCs have adapted to the 
ability of viruses to stay in endosomes by producing large 
quantities of the antiviral cytokine IFN-α and, as the virus 
slowly progresses to late endosomes, maturing into antigen-
presenting cells that initiate T cell responses. Thus, the com-
partmentalization of TLR-9–mediated response may refl  ect 
the need of PDCs fi  rst to mount an appropriate innate re-
sponse, but then switch rapidly to function at the interface of 
the innate and adaptive immune response.
MATERIALS AND METHODS
Oligonucleotide synthesis and formulations. Phosphorothioate ODNs 
were prepared as described previously (10). The prototypes for the 
ISS classes used were as follows: CpG-A (D19): 5′-GGtgcatcgatg-
cagGGGGG-3′; CpG-B (1018 ISS): 5′-T  G  A  C  T  G  T  G  A  A  C  G  T  T  C  G  A  G  A-
T  G  A  -3′; and CpG-C (C274): 5′-T  C  G  T  C  G  A  A  C  G  T  T  C  G  A  G  A  T  G  A  T  -3′. 
Uppercase letters represent PS linkages and lowercase letters represent PO 
linkages. Single-stranded version of CpG-A (CpG-A ss) was prepared by 
heating at 95°C for 5 min followed by fl  ash cooling in dry ice for 10 min. 
CpG-A (7dG) was the same sequence as D19 except that the last six gua-
nosines were substituted with 7-deaza guanosine bases. The resulting 
ODN is totally   single stranded (unpublished data). Inactive control oli-
gonucleotides were   selected based on similar lengths with same base com-
position and no CpG motif and no apparent activity (stimulatory or 
inhibitory). Fluorescent-  labeled CpG ISS were purchased from TriLink 
BioTechnologies. All ODNs had <5 endotoxin U/mg ODN, determined 
by Limulus amebocyte lysate assay (BioWhittaker). The preparation of 
1018-Ficoll400 (CpG-B Ficoll) was similar as described previously (35). 
In brief, phosphorothioate-linked 5′-1018-(CH2)3SS-(CH2)3OH was re-
duced with tris (2-carboxyethylphosphine) hydrochloride, purifi  ed  by 
RP-HPLC and used immediately in the reaction with aminoethylcar-
boxymethyl (AECM) 180-Ficoll400, which was prepared by Inman’s 
method (36). On average, there were between 35 and 134 moles of ODN 
per mole of Ficoll (MW = 400,000 D).
Isolation and stimulation of purifi   ed human cell subsets. Buff  y 
coats were obtained from the Stanford Blood Center. All cells were used 
under   Institutional Review Board–approved protocols. PBMCs were iso-
lated as described previously (10). B cells were isolated using CD19 enrich-
ment as described previously (37). Purity was routinely 99%. Experiments 
were conducted with 2 × 105 B cells per well cultured in 96-fl  at bottom 
plates. PDCs were isolated using BDCA-4 enrichment as described previ-
ously (37). PDCs were 95–99% BDCA2+ CD123+ as determined by fl  ow 
cytometry. Experiments were conducted with 5 × 104 PDCs per well 
  cultured in 96-round bottom plates. CpG and PMXB (Sigma-Aldrich; 
100 μg/ml) were added separately in the tissue culture medium and let to 
complex for 30 min at room temperature before being added to the cells as 
described previously (18).
Cytokines and antibodies. Cytokines levels were measured by ELISA. 
Human IFN-α and IL-6 production was assayed with reagents from PBL 
Biomedical Laboratories and CytoSet antibody pairs obtained from 
  BioSource, respectively. Monoclonal antibodies used for fl  ow cytometry in-
cluded: anti-CD19, anti-CD80, anti-CD86, (BD Biosciences), anti-CD123, 
and anti–BDCA-2 (Miltenyi Biotec). Monoclonal antibodies used for 
  immunofl  uorescence analysis were antitransferrin receptor (CD71) and anti–
LAMP-1 (CD107a) antibodies and were purchased from BD Biosciences.
CFSE labeling and in vitro naive T cell stimulation. Naive 
CD4+CD45RA+ T cells were prepared using a two-step approach using 
magnetic microbead labeled antibodies (Miltenyi Biotec). First, CD8-, 
CD11b-, CD16-, CD19-, CD36-, CD45R0-, and CD56-bearing cells were 
depleted and nondepleted cells were enriched for CD4. Purity was assessed 
by staining with CD4 and CD45RA antibodies and was routinely  99%. 
Cells were stained with 1 μM CFSE (Invitrogen). For coculture experi-
ments, 8 × 104 PDCs per well were stimulated with ISS for 24 h. CFSE-
  labeled allogenic naive T cells were added at a ratio of 1:2 (PDC:T cell) in 
the absence of IL-2. After 4 d, the proliferation of CFSE-labeled CD4+ 
T cells was measured by fl  ow cytometry.
Preparation of pH-sensitive liposomes. 1,2-dioleoyl-3-trimethylammo-
nium-propane (DOTAP) and l-α-phosphtidylethanolamine (PE) were ob-
tained from Avanti Polar Lipids. Cholesteryl hemisuccinate tri salt (CHEMS) 
was obtained from Sigma-Aldrich. The pH 5.75 liposomes were prepared from 
mixtures of CHEMS, DOTAP, and PE (molar ratio 20:10:4), whereas the 
pH 4.5 liposomes were prepared using CHEMS, PE (molar   ratio 45:54). Both 
preparations were made using the freeze-thawing method based on the proce-
dure of Monnard (38). Lipids were hydrated with 1.0 ml 0.125 M NaCl, 0.01 M 
Hepes, pH 8.4 buff  er containing 20 mg/ml of oligonucleotide and were frozen 
in liquid nitrogen, then thawed at room temperature fi  ve times. Nonencapsu-
lated (free) ODN was removed from the liposome preparation by gel fi  ltration 
on a 9-ml Superose 6 column (GE Healthcare) equilibrated with the 0.125 M 
NaCl, 0.01 M Hepes, pH 8.4 buff  er. Absorbance was monitored at 260 and 
310 nm, and the liposome peak at 310 nm was collected. The liposomes can be 
detected at both 310 and 260 nm (Fig. 7 A), whereas the ODN are detected 
only at 260 nm (Fig. 7 A). Liposome mean diameter, size distribution, and 
ζ potential were determined with a Nicomp 380 ZLS submicron particle sizer. 
All liposome preparations had mean diameters from 220 to 250 nm and ζ po-
tential (pH = 8.4) between −60 and −68 mV. As the pH decreased, the ζ po-
tential equilibrated until the liposomes destabilized. The concentration of 
oligonucleotide encapsulated in the liposomes was determined by capillary 
electrophoresis (CE).
Confocal microscopy. PDCs were incubated with fl  uorescent-labeled ISS 
(10 μM) for diff  erent time points (45 min, 90 min, and 4 h), washed three 
times with ice cold PBS, fi  xed in PBS medium containing 1% paraformalde-
hyde at room temperature for 15 min, and permeabilized for 10 min with 
0.25% saponin 1% BSA in PBS. Samples were blocked for 30 min using 
  Image-iT FX signal enhancer (Invitrogen) and labeled with antitransferrin 
receptor-PE or anti–LAMP-1–PE in 0.25% saponin 1% BSA in PBS. Images 
were acquired using a ZEISS LSM 510 META confocal microscope and 
a 63×/1.4 N.A. objective, with the pinhole set for a section thickness of 
0.8 μm (pinhole set to 1 airy unit in each channels). Alexa-488 or rhoda-
mine green-X (green) and PE (red) images were acquired sequentially using 
separate laser excitation to avoid any cross-talk between the fl  uorophore 
  signals. Intensity profi  les of the merged channel along randomly chosen lines 
were analyzed using the profi  le tools of the Zeiss LSM software.
Statistical analysis. Data were analyzed using a two-tailed Student’s t test. 
All analyses were performed using Prism software (GraphPad Software). 
  Diff  erences were considered signifi  cant at a p-value <0.05.
Online supplemental material. Fig. S1 shows IL-6 production from 
PDCs in response to multimeric and monomeric forms of CpG-A. Fig. S2 
describes CpG-C intracellular localization in PDCs. Fig. S3 depicts B cell 
response to liposome-encapsulated CpG-C. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20060401/DC1.
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